A FIRST IN HUMAN, PHASE I CLINICAL TRIAL OF MITOCHONDRIAL-TARGETED HSP90 INHIBITOR, GAMITRINIB IN ADVANCED AND METASTATIC PROSTATE CANCER
$905,449FY2018Department of the ArmyDOD
The Wistar Institute Of Anatomy And Biology
The Wistar Institute Of Anatomy And Biology